Agree - leronlimab is a diversified play. What will the vax companies have if they don't hit the jackpot on COVID? If some unheard of drug took COVID, CytoDyn would still likely have the most lucrative HIV franchise in that market, even before considering one or more of the many other indications.
News 
Market Data 
Discover 
